# The Post-Marketing Safety and Immunogenicity Research of Speeda® Rabies Vaccine for Human Use

> **NCT01821911** · PHASE4 · COMPLETED · sponsor: **Beijing Center for Disease Control and Prevention** · enrollment: 10500 (actual)

## Conditions studied

- Rabies Vaccine Allergy
- Vaccination Adverse Event
- Anti-D Antibodies

## Interventions

- **BIOLOGICAL:** Zagreb2-1-1
- **BIOLOGICAL:** Essen

## Key facts

- **NCT ID:** NCT01821911
- **Lead sponsor:** Beijing Center for Disease Control and Prevention
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2013-12
- **Final completion:** 2014-12
- **Target enrollment:** 10500 (ACTUAL)
- **Last updated:** 2016-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01821911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01821911, "The Post-Marketing Safety and Immunogenicity Research of Speeda® Rabies Vaccine for Human Use". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01821911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*